A U G U S T 2 0 1 9 • O U T PA T I E N T S U R G E R Y. N E T • 9 3
All cataract surgeons would like to
use intracameral antibiotics to
fight post-operative infection after
cataract surgery. Two recently
approved products could poten-
tially eliminate the compliance
issues associated with the compli-
cated steroid eye drop regimen
following cataract surgery.
• Dexycu (dexamethasone
intraocular suspension) 9%, the
first FDA-approved intraocular
steroid for the treatment of post-op inflammation, is a great example
of how we can reduce the drop burden for a patient. This is a steroid
that's injected through a single shot into the posterior chamber at the
end of cataract surgery. The sustained-release drug dissolves over the
course of a month.
• Dextenza (dexamethasone ophthalmic insert 0.4 mg) is FDA-
approved to treat both post-operative inflammation and pain. It is an
intracanalicular insert that is placed in the lower punctum following
cataract surgery. It is designed to deliver a steroid to the ocular sur-
face for 30 days following insertion.
EyePoint Pharmaceuticals
Dexycu
dexycu.com
Ocular Therapeutix
Dextenza
dextenza.com
• EYES WIDE OPEN Dr. Bailey views a video on administration
of Dexycu (dexamethasone intraocular suspension) 9%, an
intraocular steroid for the treatment of post-op inflammation.
